You advertise GLP-1 and weight-loss telehealth on Meta and Google without getting flagged by running condition-education creative through policy-compliant landing paths, not direct product-and-result ads. Both platforms allow weight-loss telehealth advertising in 2026. What they reject is the specific creative and landing-page pattern most brands reach for first: named GLP-1 medications, before-and-after photos, weight numbers, and copy that implies the platform knows a viewer is overweight. Get the compliance discipline right and the channel stays open. Get it wrong and a single flag can freeze an account for a week. These are agency averages across active telehealth accounts, not guarantees.
ClinicAds already publishes a complete telehealth marketing guide that covers GLP-1 policy in a single section. This post is the full platform-by-platform playbook: why Meta and Google flag these ads, exactly what each policy allows, how to frame creative and landing pages that survive review, and what to do when an ad still gets rejected. If you run one weight-loss telehealth brand and need the operational detail rather than the overview, this is the deep dive.
- GLP-1 and weight-loss telehealth can be advertised on both Meta and Google in 2026. The ads are allowed; the rejections come from creative and landing pages that violate weight-loss and prescription-drug policy, not from the vertical being banned.
- Meta rejects before-and-after imagery, negative self-perception, body-part close-ups, named prescription weight-loss drugs, and personal-attribute language, and restricts weight-loss ads to viewers 18 and older.
- Google treats prescription GLP-1 medication as restricted pharmaceutical content and generally requires LegitScript certification for the telehealth provider before online-pharmacy and prescription-drug ads can run.
- A compliant GLP-1 patient costs roughly $150 to $250 to acquire against a $600 to $2,000 lifetime value, so surviving ad review is the difference between a profitable channel and a frozen account. These are agency averages, not guarantees.
Can you advertise GLP-1 and weight-loss telehealth in 2026?
Yes. GLP-1 and weight-loss telehealth can be advertised on both Meta and Google in 2026, but only through condition-education creative and policy-compliant landing paths. The vertical is not banned. What gets rejected is a predictable set of creative and landing-page choices: named prescription medications such as semaglutide or tirzepatide in ad copy, before-and-after body imagery, specific weight-loss numbers, and language that implies the platform knows the viewer's body or health status. GLP-1 weight loss is among the fastest-growing telehealth categories, which means review teams see high volumes of policy-violating ads in this space and apply extra scrutiny. The brands that keep campaigns live treat compliance as a creative and landing-page discipline rather than a targeting workaround. These are agency averages, not guarantees.
Why do Meta and Google flag GLP-1 and weight-loss ads?
Meta and Google flag GLP-1 and weight-loss ads because these ads sit under each platform's most restrictive health and pharmaceutical policies, and most telehealth creative violates those policies by default. Meta prohibits ads that imply knowledge of a viewer's personal health condition, along with before-and-after images and content that promotes negative self-perception. Google classifies prescription GLP-1 drugs as restricted pharmaceutical content that requires certification before it can run. A flag is rarely a mistake by the reviewer. It is usually the ad doing exactly what the policy forbids: naming the drug, showing the result, or targeting people by their weight. Understanding which specific rule an ad trips is the whole job, because each platform disallows different things for different reasons.
- Meta: personal-attribute language, before-and-after imagery, negative self-perception, named prescription drugs
- Google: prescription-drug and online-pharmacy restrictions requiring certification
- Both: weight-loss content carries extra review scrutiny because violation rates are high
What does Meta's policy allow for weight-loss telehealth ads?
Meta allows weight-loss telehealth ads that describe the clinical program and general eligibility rather than the drug and the result. Meta's personal-attributes policy prohibits copy that asserts or implies knowledge of a viewer's weight or health condition, so "Struggling with your weight?" framed as a direct assertion about the viewer is a common rejection, while a general description of who a medical weight-management program serves is not. Meta also prohibits before-and-after images, close-ups of body parts, and content that promotes negative self-perception, and it restricts weight-loss ads to an audience of viewers 18 and older. Compliant Meta creative for GLP-1 leads with the medical program, the clinical oversight, and the condition, and it shows the provider and the process instead of a transformed body.
- Allowed: general program description, clinical oversight, condition education, provider and process imagery
- Prohibited: before-and-after photos, body-part close-ups, negative self-perception
- Prohibited: personal-attribute copy implying the platform knows the viewer's weight or health
- Prohibited: named prescription weight-loss drugs in creative
- Required: weight-loss ads restricted to viewers 18 and older
What does Google's policy require for GLP-1 advertising?
Google requires telehealth brands advertising prescription GLP-1 medication to be certified before online-pharmacy and prescription-drug ads can run, and it restricts how and where those ads appear. In practice this means LegitScript certification for the telehealth provider, which Google uses as its gate for online pharmacies and telemedicine advertisers, plus a Google pharmaceutical or healthcare certification tied to the account. Google restricts branded prescription-drug terms and frequently disapproves landing pages that sell prescription weight-loss medication without the required certification. Search campaigns for GLP-1 must route to policy-reviewed landing paths, and the certification process takes time, so a brand that starts advertising the day it wants to launch has usually not left room for review. The table below compares what each platform requires.
| Policy area | Meta | |
|---|---|---|
| Named prescription drug in creative | Prohibited | Restricted, certification-gated |
| Before-and-after or body imagery | Prohibited | Discouraged, high disapproval risk |
| Provider certification | Not the primary gate | LegitScript plus Google pharma cert typically required |
| Targeting by weight or health attribute | Prohibited (personal attributes) | Not the primary gate |
| Audience age restriction | 18 and older for weight loss | Governed by drug and healthcare policy |
| Compliant path | Condition-education creative, general eligibility | Certified account, policy-reviewed landing page |
How should you frame GLP-1 creative so it survives review?
You frame GLP-1 creative to survive review by leading with the condition and the clinical process instead of the drug and the result. The reliable pattern across both platforms is to describe a medically supervised weight-management program, name the type of care rather than the specific medication, speak to the viewer as a general audience rather than as a person the platform has profiled, and show the provider or the process rather than a transformed body. This is not a softer version of the same ad. It is a different ad built to a policy, and the brands that treat it that way keep a bench of approved variants ready so testing never stops.
- Lead with the condition and the medically supervised program, not the branded drug
- Describe general eligibility, never assert knowledge of the viewer's weight
- Show the provider, the clinical process, or the consultation, not before-and-after bodies
- Keep three to five approved creative variants queued so a single flag never stops testing
- Route every ad to a landing page that matches the compliance level of the creative
What should a compliant GLP-1 landing page include?
A compliant GLP-1 landing page discloses medical oversight, describes eligibility and the clinical process, avoids guaranteed-outcome claims, and never carries a patient's protected health information in its URL. Ad reviewers and certification bodies check the landing page, not only the ad, so a compliant ad pointed at a non-compliant page still gets disapproved. The page should make clear that a licensed clinician evaluates every patient, that the medication is prescription-only and dispensed after evaluation, and that outcomes vary. On the tracking side, the page must not pass identifiers or condition data to advertising pixels, because Meta and Google do not sign Business Associate Agreements, and PHI in a confirmation URL is a HIPAA exposure separate from ad policy. That is the same server-side, PHI-stripped tracking standard the Cerebral and BetterHelp FTC actions made non-negotiable.
- State that a licensed clinician evaluates eligibility before any prescription
- Describe the clinical process and general eligibility, not guaranteed weight loss
- Avoid before-and-after imagery and specific outcome numbers on the page
- Strip PHI from confirmation URLs and measure conversions server-side, not through a default pixel
How do you recover when a GLP-1 ad gets flagged?
You recover from a flag by rotating to an approved variant immediately, appealing the specific rejection through the platform, and diagnosing which rule the ad tripped so the next asset does not repeat it. The failure mode that costs brands the most is treating a single rejection as a stop rather than a switch. A prepared account never has all of its spend riding on one creative, so a flag pauses one ad while approved variants keep running. Follow these four steps in order.
- Rotate live spend to a pre-approved variant so the campaign does not go dark
- Read the specific policy citation in the rejection rather than guessing at the cause
- Appeal through the platform's review process when the rejection looks like a false positive
- Fix the actual violation in a new asset, then add it back to the approved bench
What does compliant GLP-1 patient acquisition cost?
A compliant GLP-1 or weight-loss telehealth patient costs roughly $150 to $250 to acquire in 2026, the higher end of the telehealth range, because ad-policy restrictions narrow targeting and force education-first creative. That cost is only meaningful against lifetime value and payback, since telehealth is a subscription: a paying patient is worth $600 to $2,000 over the relationship, the target is an LTV-to-CAC ratio of 3:1 or better, and payback should land inside 3 months. This is why surviving ad review matters in dollar terms and not only in compliance terms. A brand that loses a week of spend to each flag is not just non-compliant, it is paying a higher effective CAC on a channel it could be running cleanly. These are agency averages, not guarantees.
- GLP-1 and weight-loss CAC: $150 to $250, the high end of the telehealth range
- Patient lifetime value: $600 to $2,000 depending on retention
- Targets: 3:1 or better LTV-to-CAC, payback under 3 months
What are the most common GLP-1 advertising mistakes?
The most common GLP-1 advertising mistakes are compliance failures a brand can see coming and prevent. Avoiding these five is most of what keeps a weight-loss telehealth account live and profitable rather than frozen and appealing.
- Naming the medication and showing the result, the two fastest routes to a Meta rejection
- Starting Google campaigns before LegitScript and pharmaceutical certification are in place
- Running a compliant ad to a non-compliant landing page that gets the whole ad disapproved
- Riding all spend on one creative, so a single flag freezes the account
- Using a default client-side pixel that sends patient data to a platform with no BAA
Can you advertise GLP-1 weight-loss telehealth on Meta and Google?
Yes. Both platforms allow weight-loss telehealth advertising in 2026. The rejections come from creative and landing pages that violate policy, not from the vertical being banned. Compliant campaigns use condition-education creative and policy-reviewed landing paths.
Why does Meta keep rejecting my weight-loss ads?
Meta prohibits before-and-after imagery, body-part close-ups, negative self-perception, named prescription weight-loss drugs, and personal-attribute copy that implies it knows a viewer's weight or health. Most rejections trace to one of these. Compliant creative describes the medical program in general terms instead.
Do you need LegitScript to advertise GLP-1 on Google?
Generally yes. Google gates online-pharmacy and prescription-drug advertising, including prescription GLP-1 medication, behind certification, and uses LegitScript certification of the telehealth provider plus a Google pharmaceutical or healthcare certification. Landing pages selling prescription weight-loss medication without it are routinely disapproved.
What does a compliant GLP-1 patient cost to acquire?
Roughly $150 to $250 in 2026, the high end of the telehealth range, because ad-policy restrictions narrow targeting. Against a $600 to $2,000 lifetime value with payback under 3 months, the channel is profitable when campaigns survive review. These are agency averages, not guarantees.
Is this legal or compliance advice?
No. This is general information about advertising-platform policy, not legal or compliance advice. A telehealth brand should have its ad creative, landing pages, and tracking reviewed for policy and HIPAA compliance and sign a Business Associate Agreement with any vendor that handles patient data.